Trials / Unknown
UnknownNCT05287165
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 19 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms
Conditions
- Advanced Solid Tumors
- Digestive System Neoplasms
- Pancreatic Cancer Resectable
- Colorectal (Colon or Rectal) Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IM96 CAR-T cells | treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion |
Timeline
- Start date
- 2022-03-10
- Primary completion
- 2024-04-30
- Completion
- 2024-06-30
- First posted
- 2022-03-18
- Last updated
- 2022-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05287165. Inclusion in this directory is not an endorsement.